Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 2/20 | 0.54 |
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.48 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.48 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | RGS12 | O14924 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL132439 | 0.97 | XDH (0.59) | XDHKDM4EPTGS2RAB9AMAPT | |
| SCHEMBL27935044 | 0.97 | XDH (0.59) | XDHKDM4EPTGS2RAB9AMAPT | |
| SCHEMBL31122716 | 0.94 | XDH (0.57) | XDHKDM4EPTGS2RAB9AMAPT | |
| Alcohol SCHEMBL28845727 | 0.85 | XDH (0.50) | XDHKDM4EPTGS2RAB9ATDP1 | |
| Benzaldehyde SCHEMBL17963717 | 0.84 | ALDH1A1 (0.61) | XDHKDM4EPTGS2RAB9AALDH1A1 | |
| SCHEMBL30822600 | 0.82 | XDH (0.52) | XDHKDM4EPTGS2RAB9AALDH1A1 | |
| SCHEMBL1056033 | 0.82 | XDH (0.52) | XDHKDM4EPTGS2RAB9AALDH1A1 | |
| SCHEMBL1527073 | 0.82 | XDH (0.52) | XDHKDM4EPTGS2RAB9AALDH1A1 | |
| SCHEMBL299751 | 0.80 | EGFR (0.53) | XDHKDM4EPTGS2RAB9AMAPT | |
| SCHEMBL7962088 | 0.80 | XDH (0.50) | XDHKDM4EPTGS2RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1300486-B1 | Plating bath and method for depositing a metal layer on a substrate | SHIPLEY CO LLC (US) | 2011-03-16 | — | — | EP | claimed |
| US-20040074778-A1 | Plating bath and method for depositing a metal layer on a substrate | SHIPLEY COMPANY, L.L.C. (US) | 2004-04-22 | — | — | US | claimed |
| US-6652731-B2 | Comprises 2,3,4-trihydroxybenzaldehyde for inhibiting consumption of plating additives; integrated circuits | SHIPLEY COMPANY, L.L.C. | 2003-11-25 | — | — | US | claimed |
| US-20030085132-A1 | Plating bath and method for depositing a metal layer on a substrate | SHIPLEY COMPANY, L.L.C. | 2003-05-08 | — | — | US | claimed |
| EP-1300486-A1 | Plating bath and method for depositing a metal layer on a substrate | Shipley Co. L.L.C. (US) | 2003-04-09 | — | — | EP | claimed |
| WO-2023209250-A1 | PYRIMIDO[5,4-D]PYRIMIDINE-BASED COMPOUNDS, METHODS AND USES THEREOF | UNIVERSIDADE DO MINHO (PT) | 2023-11-02 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11117987-B2 | Hydroxyaryl functionalized polymers | BRIDGESTONE CORPORATION (JP) | 2021-09-14 | — | — | US | disclosed |
| US-11028195-B2 | Hydroxyaryl functionalized polymers | BRIDGESTONE CORPORATION (JP) | 2021-06-08 | — | — | US | disclosed |
| US-20190322777-A1 | Hydroxyaryl Functionalized Polymers | BRIDGESTONE CORPORATION (JP) | 2019-10-24 | — | — | US | disclosed |
| US-20190233557-A1 | Hydroxyaryl Functionalized Polymers | BRIDGESTONE CORPORATION (JP) | 2019-08-01 | — | — | US | disclosed |
| US-10227425-B2 | Hydroxyaryl functionalized polymers | BRIDGESTONE CORPORATION (JP) | 2019-03-12 | — | — | US | disclosed |
| EP-1300486-A1 | Plating bath and method for depositing a metal layer on a substrate | Shipley Co. L.L.C. (US) | 2003-04-09 | — | — | EP | disclosed |
| US-20030022923-A1 | Methods for treatment of sickle cell anemia | MEDINOX, INC. | 2003-01-30 | — | — | US | disclosed |
| EP-1173174-A4 | METHODS FOR TREATMENT OF SICKLE CELL ANEMIA | MEDINOX INC (US) | 2002-09-18 | — | — | EP | disclosed |
| US-6355661-B1 | STABILITY OF ALDEHYDES AND PROTECTED ALDEHYDES | MEDINOX, INC. | 2002-03-12 | — | — | US | disclosed |
| EP-1173174-A1 | METHODS FOR TREATMENT OF SICKLE CELL ANEMIA | Medinox, Inc. (US) | 2002-01-23 | — | — | EP | disclosed |
| US-6251927-B1 | TREATING SICKLE CELL ANEMIA USING PROTECTED FORMS OF ORGANIC ALDEHYDES | MEDINOX, INC. | 2001-06-26 | — | — | US | disclosed |
| WO-2000062777-A1 | METHODS FOR TREATMENT OF SICKLE CELL ANEMIA | MEDINOX, INC. (US) | 2000-10-26 | — | — | WO | disclosed |
| EP-0667245-A1 | Recording sheets containing alcohols and saccharides | XEROX CORPORATION (US) | 1995-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322777-A1 | Hydroxyaryl Functionalized Polymers | HAAO, HCAR3, VCL | PTGS2 1427/4885MEN1 4721/4885EGFR 3863/4885 |
| US-11028195-B2 | Hydroxyaryl functionalized polymers | HAAO, HCAR3, VCL | PTGS2 1552/4885MEN1 4769/4885EGFR 3989/4885 |
| US-10227425-B2 | Hydroxyaryl functionalized polymers | HAAO, HCAR3, VCL | PTGS2 1427/4885MEN1 4721/4885EGFR 3863/4885 |
| US-20030022923-A1 | Methods for treatment of sickle cell anemia | SORD, HBG1, HBG2 | PTGS2 894/4885MEN1 4307/4885EGFR 4884/4885 |
| US-11117987-B2 | Hydroxyaryl functionalized polymers | HAAO, HCAR3, VCL | PTGS2 1427/4885MEN1 4721/4885EGFR 3863/4885 |
| US-20190233557-A1 | Hydroxyaryl Functionalized Polymers | HAAO, HCAR3, VCL | PTGS2 1552/4885MEN1 4769/4885EGFR 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.